The Clinic Study of Therapy in the Chronic Myelocytic Leukemia-Chronic Phase by As_2O_3 Combined with Homoharringtoninum
- VernacularTitle:CML慢性期三氧化二砷联合高三尖杉酯碱治疗的临床探讨
- Author:
Zhiguo HE
;
Lijun HOU
;
Jingbo XU
;
Linjuan ZENG
;
Shuping ZHONG
- Publication Type:Journal Article
- Keywords:
Arsenic trioxide;
Homoharringtoninum;
Chronic myelocytic leukmia/chronic phase;
Chemotherapy
- From:
Journal of Medical Research
2006;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effctiveness and safety of arsenic trioxide(As2O3)combined with Homoharringtoninum in the chronic myelocytic leukmia-chonic phase(CML-CP).Methods Seven patients were treated with As2O3 10mg per day for 2~3 week and with Homoharringtoninum 3~4mg per day for 1~2.Results All patients were clinic remission,of which there were 4 complete remission who were all initial therapy,and 3 partial remission,2 of who were initial therapy and 1 was resume threapy.4 patients of CR were treated with second strengthen therapy and continued hematologic CR.The main side effects were grade 3 hematologic toxicity and light liver damage,and no significant nausea,emesis,diarrhea or mucositis.Conclusion As2O3 combined with Homoharringtonium in the CML-CP is a safe and effctive regimen.
